Our team is driven by an inspiration in the primary cell-based field. We believe that more representative cell models will bring representativity to drug discovery.
Spheroids, organoids, 2D primary cell cultures, biological scaffolds and microphisiological systems are confidently becoming the reality of an industry.
We aim to drive that industry with bringing more donor-derived materials, better in quality and cost efficiency.
Preci is concerned about ethics of human biological sample acquisitions.
We developed an internal code of conduct which strictly requires every biological material to be collected anonimously, through the network of autorized clinical sites with respect to the volonteering nature of the donation.
to a study
Ability to acquire
Ability to clearly
Represent the disease
Less then 20% of clinial cases get into study
Disease is clearly
the phenotypic req’s
Patient is treatment-
-resistant or naive
Contact us to audit clinical compliance yourself